RxDoctor Payments Data

Pridhvi Yelamanchili, MD

Interventional Cardiology · Mesa, AZNPI 1790730604

Payments from drug & device makers

$14,900in general payments, 2019–2025

Across 261 payments — averaging $57.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Endologix LLC$2K
  • Amgen$598
  • AstraZeneca$572
  • Novartis$387
  • Abiomed$387
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$6,17541%
  • Food & beverage$8,53857%
  • Education$1871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,900 in reported general payments places this provider in the 50th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$859,280
Medicare patients
1,118
Services billed
4,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$559,271
BrilintaTicagrelor324$288,337
EntrestoSacubitril/Valsartan118$122,232
Repatha SureclickEvolocumab90$101,821
XareltoRivaroxaban89$91,907
FarxigaDapagliflozin Propanediol29$40,005
Metoprolol Succinate902$11,327
Amiodarone Hcl98$6,844
ClopidogrelClopidogrel Bisulfate582$6,778
Rosuvastatin Calcium380$6,561
Atorvastatin Calcium606$6,351
Ranolazine ErRanolazine83$5,896
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide230$4,128
Carvedilol471$3,990
Losartan Potassium334$3,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$279$559,271437 claims
AstraZenecaBrilinta, Farxiga$572$328,342353 claims
NovartisEntresto$387$122,232118 claims
Johnson & JohnsonXarelto$213$91,90789 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →